Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
We will test our primary hypothesis that combining niacin extended release (niacin-ER), at a
daily dosage of up to 2.0 g with pioglitazone, at a daily dosage of 45 mg will result in a
12% greater increase in HDL-C when compared to niacin-ER monotherapy over 12 weeks in
non-diabetic patients with the metabolic syndrome (see Table 1).